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• Etiology of NCM is unclear and it is unknown if stimulant medications 
contributed to patient’s presentation. 
• Given risk of increasing heart rate which may exacerbate cardiac issues, stimulant 
medications were held. 
• It is important to monitor patients on stimulant medications for cardiovascular 
complication throughout their treatment. 
• Stimulant use for treatment of ADHD requires evaluation of risks and benefits at 
initiation, continuation and discontinuation of medications. 
• There is no specific set of guidelines available for prescribing stimulants. 
However, if a patient is noted to have cardiovascular risk factors then further 
evaluation, medication adjustment and cardiology consultation should be 
considered. 
• Further research is needed to understand the cardiovascular risk of patients in the 
setting of stimulant use to make appropriate risk-benefit decisions. 
Stimulant Discontinuation for ADHD Treatment in a Patient 
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• To understand the importance of monitoring and screening for cardiovascular risk 
factors in patients prescribed stimulants for treatment of Attention 
Deficit/Hyperactive Disorder (ADHD). 
• To recognize that cardiac issues can impact stimulant prescribing and may result 
in life threatening complications. 
• To develop an appreciation of the repercussions of complications and untreated 
ADHD symptoms from discontinuation of stimulants.
• To recognize the importance of collaborative care across specialties in treating 
patients.
• Non-compaction cardiomyopathy (NCM) is largely a genetic condition due to 
failure of left ventricular compaction resulting in extensions of bundles of muscle 
(trabeculations) into the chamber. This impairs the ability of cardiac muscle to 
contract or relax adequately (4).
• Diagnosis for NCM can occur at any age. Patients may be asymptomatic though 
there is a risk of complications including cardiac arrest, blood clots and heart 
failure (4).
• ADHD is defined as a persistent pattern of inattention and/or 
hyperactivity/impulsivity that interferes with functioning which is inappropriate 
for an individual’s developmental level (1).
• ADHD contributes to academic, social and occupational functioning and is 
prevalent in 4.4% of adults in the United States (3).
• Psychostimulants and non-stimulant medications may be used to treat symptoms 
of ADHD.
• Stimulant medications may impact heart rate, heart rhythm, blood pressure and 
QTc which can increase risk of cardiovascular complications including sudden 
death. (Figure 2). 
• Cardiovascular safety of ADHD medications in adults is not completely 
understood with variance of results. 
• In adults aged 25 – 64 years old, the US Food and Drug Administration (FDA) did 
not find an increased risk of myocardial infarction, stroke or sudden cardiac death 
with stimulant use for ADHD (FDA).
• FDA does not recommend stimulant use in patients with heart problems, 
problematic elevated blood pressure or heart rate. 
• Development of cardiomyopathy in patients using stimulants is rare in younger 
age groups. The highest rates occurred in individuals age 65 or older (5).
• Use of stimulants (lisdexamfetamine, metyhlphenidate and atomoxetine) was not 
associated with a higher rate of heart failure or cardiomyopathy over 3 years of 
use (5).
• Pre-existing cardiovascular conditions reduces likelihood of use of stimulant 
therapy for treatment of ADHD. (2).
• There are no established monitoring guidelines for patients on stimulant 
medications for ADHD.
31-year-old female with a past medical history of ADHD, low BMI and clubbed 
feet. She was evaluated on an outpatient basis with the following timeline:
• Referred to HFH Behavioral Health Services in 2016 and diagnosed with ADHD 
(combined type). 
• Prior medications trials included dextroamphetamine-amphetamine IR and XR 
formulations (though benefitted only with IR). Started on dextroamphetamine-
amphetamine IR 20mg twice daily.
• At follow up 4 months later she was noted to be tachyardic to 120 beats per 
minute.  Dose adjusted to dextroamphetamine-amphetamine IR 10mg twice daily.
• EKGs showed right axis deviation, possible left atrial enlargement, non-specific T-
wave abnormality and QTc of 483ms (on repeat 1 month later was 425ms).
• Referred to Rheumatology
• Full evaluation done with workup only notable for speckled pattern ANA.  
Remaining studies unremarkable.  Lupus felt to be unlikely.
• Referred to Cardiology
• Initial workup included ECHO which showed EF of 34.7%, left wall 
hypokinesis, mild diastolic dysfunction of LV, upper normal right ventricular 
size and moderately reduced RV systolic pressure.
• Event monitor for 7 days which only showed sinus tachycardia.
• Eventually started on carvedilol 3.15mg twice daily and lisinopril 2.5mg daily.
• Later diagnosed with Generalized Anxiety Disorder and started on buspirone
7.5mg twice daily, but this was discontinued 2 weeks later due to emotional 
lability.
• Trialed other stimulants included atomoxetine (discontinued due to drowsiness) as 
well as methylphenidate.  Initially did well on methylphenidate at 72mg with 
improvement in both tachycardia and ADHD symptoms, but tachycardia later 
returned and persisted despite decreases in dosage.
• Given cardiac issues all stimulants were then discontinued.  Since then has had 
symptoms of ADHD, struggles with employment stressors and learned that she is 
unable to have children due to cardiac issues. 
• No widely accepted recommendations for screening/monitoring in setting of 
stimulant use for treatment of ADHD. 
• Given the varying opinions, it is important to: 
• Obtain thorough medical, social and family history (especially of sudden death 
in young individuals, arrhythmias, prolonged QT, hypertrophic 
cardiomyopathy, genetic cardiac conditions, Marfan syndrome, etc.) 
• Physical exam
• Vitals (heart rate and blood pressure) should be checked  prior to starting 
stimulant medications and routinely during treatment. 
• Routine EKG for screening is not required for each patient. However, it should 
be obtained if cardiac risk factors or clinically warranted due to symptoms.  
• Consider cardiology consultation if indicated by history, physical exam and 
work-up.
1. American Psychiatry Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: 
American Psychiatric Publishing. 
2. Gerhard T, Wintersetin A, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult 
ADHD. Pharmacoepidemiology and Drug Safety. 2010;(19)457-464.
3. Kessler R, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the 
National Comorbidity Survey Replication. American Journal of Psychiatry. 2006;163(4)716-723.
4. Left Ventricular Non-compaction Cardiomyopathy (LVNC) [Internet]. Cincinnati Children’s. 2018 [cited 2019 Apr 2019]; 
Available from: https://www.cincinnatichildrens.org/service/c/cardiomyopathy/types/left-ventricular-non-compaction-
cardiomyopathy
5. Mosholder A, Taylor L, Mannheim G, et al. Incidence of Heart Failure and Cardiomyopathy Following Initiation of 
Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. Journal of Clinical Psychopharmacology. 
2018;38(5)505-508.
6. Vetter V, Elia J, Erikson C, et al. Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving 
Medications for Attention Deficit/Hyperactivity Disorder. AHA Scientific Statement. 2008;(117)2407-2423. 
Figure 2: From (6) for “Cardiac Effects of Medications 
Used to Treat ADHD.” 
D: dopamine
NE: norepinephrine
NT: neurotransmitter
HR: heart rate
BP: blood pressure
S: serotonin. 
Figure 1: Comparison of 
normal heart (left) and heart 
with left ventricular non-
compaction cardiomyopathy 
(right) (4).
